The ratio of debt to operating expenses for Natural Health Trends Corp is higher than it is for about only 8.73% of US stocks.
As for revenue growth, note that NHTC's revenue has grown -49.61% over the past 12 months; that beats the revenue growth of merely 3.66% of US companies in our set.
Natural Health Trends Corp's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 16.68%, greater than the shareholder yield of 86.65% of stocks in our set.
Stocks that are quantitatively similar to NHTC, based on their financial statements, market capitalization, and price volatility, are OPY, DXPE, LAZ, ARCB, and RVLV.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $24 million investment from the U.S. Department of Defense in collaboration with the U.S. Department of Health and Human Services to support the scale up of U.S. manufacturing capabilities for BD Veritor™ Solution for Rapid Detection of SARS-CoV-2 (see demo here).
HONG KONG, July 29, 2020 (GLOBE NEWSWIRE) -- Natural Health Trends Corp. (NASDAQ: NHTC), a leading direct-selling and e-commerce company that markets premium quality personal care, wellness, and “quality of life” products under the NHT Global brand, today announced the Company will report its financial results for the second quarter ended June 30, 2020 on Wednesday, August 5, 2020 at 9:00 a.m. Eastern Time. Chris Sharng, Natural Health Trends’ President, and Scott Davidson, Senior Vice President and Chief Financial Officer, will host a conference call to discuss the second quarter 2020 financial results on the same day at 11:30 a.m. Eastern Time. The details for the conference call can be found below. Second Quarter 2020 Financial Results Conference CallDate:Wednesday, August 5, 2020 ...
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 per common share, payable on September 30, 2020 to holders of record on September 9, 2020. The indicated annual dividend rate is $3.16 per share. In addition, the Board of Directors has declared a quarterly dividend of $15.8333334 per share on the 6.00% mandatory convertible preferred stock, Series B, payable on September 1, 2020 to holders of record on August 15, 2020. This represents $0.79166667 per depositary share (NYSE: BDXB).
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it received approval for a pre-market approval (PMA) supplement from the U.S. Food and Drug Administration (FDA) for an expanded version of its BD Onclarity™ HPV Assay. The PMA supplement includes the expansion for genotype reporting beyond HPV genotypes 16, 18, and 45 to include types 31, 51, 52, 33/58, 35/39/68, and 56/59/66 genotypes making the BD Onclarity™ HPV Assay the only FDA-approved assay to individually identify and report these genotype results.